Drug intelligence / Profile preview

SPA1

Development stage: Preclinical
Lead developer: Sinphar Pharmaceutical

Overview

SPA1 is a botanical drug candidate developed by Sinphar Pharmaceutical, derived from natural plant materials. It is being investigated as an adjuvant therapy for cancer and for its immune-modulating effects. While it remains in the preclinical stage of pharmaceutical development, the compound has already received health food certification for immune modulation in Taiwan. Its primary function is to regulate immune system activity to support therapeutic outcomes in oncology settings.

Beyond the preview

Go deeper on SPA1.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SPA1.

Explore the full profile